Patents by Inventor Scott E. Lazerwith

Scott E. Lazerwith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20240239807
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: August 4, 2023
    Publication date: July 18, 2024
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • Phospholipid compounds and uses thereof
    Patent number: 12030904
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: July 9, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Devan Naduthambi, Thomas P. Stratton, Peiyuan Wang
  • THIENOPYRROLE COMPOUNDS
    Publication number: 20240217990
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Application
    Filed: February 8, 2022
    Publication date: July 4, 2024
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Julian A. Codelli, Lan Jiang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Scott D. Schroeder, Daniel G. Shore
  • Phospholipid compounds and uses thereof
    Patent number: 11963967
    Abstract: Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: April 23, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Thomas P. Stratton, Peiyuan Wang
  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20240116946
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: October 3, 2023
    Publication date: April 11, 2024
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • SUBSTITUTED INDOLE COMPOUNDS
    Publication number: 20240059673
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 22, 2024
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Scott E. Lazerwith, Daniel G. Shore
  • PHOSPHOLIPID COMPOUNDS AND USES THEREOF
    Publication number: 20240025932
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Application
    Filed: June 9, 2023
    Publication date: January 25, 2024
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Devan Naduthambi, Thomas P. Stratton, Peiyuan Wang
  • KRAS G12D MODULATING COMPOUNDS
    Publication number: 20230374036
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 20, 2023
    Publication date: November 23, 2023
    Inventors: Chaodi Dai, Juan A. Guerrero, Tezcan Guney, Hongyan Guo, Darryl Kato, Irene N. Kiburu, Scott E. Lazerwith, Jessica L. McKinley, Jonathan William Medley, Hyung-Jung Pyun, Maoqun Tian, Vickie H. Tsui, William J. Watkins, Adam D. Zajdlik, Jennifer R. Zhang
  • THIENOPYRROLE COMPOUNDS
    Publication number: 20230365594
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Application
    Filed: March 8, 2023
    Publication date: November 16, 2023
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore, Christopher J. Swank
  • KRAS G12D MODULATING COMPOUNDS
    Publication number: 20230339981
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 14, 2023
    Publication date: October 26, 2023
    Inventors: Chaodi DAI, Juan A. GUERRERO, Tezcan GUNEY, Hongyan GUO, Darryl KATO, Irene N. KIBURU, Scott E. LAZERWITH, Jessica L. MCKINLEY, Jonathan William MEDLEY, Hyung-Jung PYUN, Maoqun TIAN, Vickie H. TSUI, William J. WATKINS, Adam D. ZAJDLIK, Jennifer R. ZHANG
  • CAPSID INHIBITORS FOR THE TREATMENT OF HIV
    Publication number: 20230312567
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Application
    Filed: February 15, 2023
    Publication date: October 5, 2023
    Inventors: Chienhung Chou, Darryl Kato, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • MCL-1 INHIBITORS
    Publication number: 20230312490
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: March 9, 2023
    Publication date: October 5, 2023
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Phospholipid compounds and uses thereof
    Patent number: 11773122
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: October 3, 2023
    Assignee: Gilead Sciences. Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Devan Naduthambi, Thomas P. Stratton, Peiyuan Wang
  • THIENOPYRROLE COMPOUNDS
    Publication number: 20230270734
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Application
    Filed: September 8, 2022
    Publication date: August 31, 2023
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore
  • SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF
    Publication number: 20230270719
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: November 29, 2022
    Publication date: August 31, 2023
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • PHOSPHOLIPID COMPOUNDS AND USES THEREOF
    Publication number: 20230248753
    Abstract: Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Application
    Filed: April 20, 2023
    Publication date: August 10, 2023
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Thomas P. Stratton, Peiyuan Wang
  • PHOSPHOLIPID COMPOUNDS AND USES THEREOF
    Publication number: 20230250117
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Devan Naduthambi, Thomas P. Stratton, Peiyuan Wang
  • Capsid inhibitors for the treatment of HIV
    Patent number: 11680064
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 20, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Darryl Kato, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Thienopyrrole compounds
    Patent number: 11661431
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: May 30, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore, Christopher J. Swank
  • SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF
    Publication number: 20230148157
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: July 12, 2022
    Publication date: May 11, 2023
    Inventors: David Alan Gutierrez, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Philip Anthony Morganelli, Hyung-Jung Pyun